22 / 28
Summary
• Durvalumab demonstrated a statistically significant and robust improvement in PFS versus
placebo (HR 0.52; P<0.0001; median improvement of >11 months) at a planned interim
analysis
• PFS improvement with durvalumab was observed across all pre-specified subgroups
• Durvalumab demonstrated a clinically meaningful benefit in ORR (28.4% vs 16.0%; P<0.001),
with durable responses versus placebo (median DoR not reached vs 13.8 months)
• Patients receiving durvalumab had a lower incidence of new lesions, including new brain
metastases, compared with patients receiving placebo
• The safety profile of durvalumab was consistent with that of other immunotherapies and with
its known safety profile as monotherapy in patients with more advanced disease;
1
no new
safety signals were identified
• The study remains blinded to OS